Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

Dasatinib 4nilotinib 3Imatinib Mesylate 3ruxolitinib 2bosutinib 2Tacrolimus 2Mycophenolic Acid 2Methotrexate 2Cyclosporine 2Cyclophosphamide 2venetoclax 1ponatinib 1pembrolizumab 1letermovir 1fludarabine phosphate 1asciminib 1Whole-Body Irradiation 1Vorinostat 1Valganciclovir 1Tyrosine Kinase Inhibitors 1Therapeutics 1Specimen Handling 1Sirolimus 1Polymerase Chain Reaction 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Ganciclovir 1Foscarnet 1Flow Cytometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myeloid, Chronic-Phase × ruxolitinib × Clear all
NCT03610971 2026-04-02

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

SWOG Cancer Research Network

Phase 2 Active not recruiting
81 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡